Thermo Fisher Scientific has absorbed HighChem, the Bratislava, Slovakia-based developer and trademark holder of the Mass Frontier mass spectrometry software used to identify the structures of small molecules.
HighChem’s work will be fully integrated into the chromatography and mass spec business within the company’s analytical instruments segment, though Thermo Fisher itself has been offering Mass Frontier for years. The financial terms of the deal were not disclosed.
HighChem and its small team of employees also develop library and cloud-based systems and maintain large data collections of fragmentation knowledge, experimental spectra and organism-specific biochemical data for use in biopharmaceutical, metabolomic, forensic and environmental applications.
Earlier this year, Thermo Fisher announced plans to invest $150 million in its services aimed at the pharmaceutical industry, including adding capacity for product development and manufacturing.
It plans to expand three of its CDMO locations in North Carolina and Italy over the next two years. Thermo Fisher had jumped headlong into the contract manufacturing business with its $7.2 billion deal for Patheon in 2017.
Its $1.7 billion acquisition of viral vector developer and manufacturer Brammer Bio also gave it a foothold in the cell and gene therapy market. Thermo Fisher estimates the addition will deliver $250 million in annual revenue by the end of the year, and expects its growth to outpace the 25% rate projected for that sector.